FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

Artificial intelligence (AI) is now an essential tool in biopharma manufacturing, yet industry still needs guidelines on how LLMs, ML, and other technologies should be used in drug making, say the ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

Researchers are preparing for the arrival of a new state‑of‑the‑art instrument that will accelerate studies into some of the ...

By Vijay Kumar Malesu Why mismatched resistance thresholds between CLSI and EUCAST could be masking the true scale of ...

April M. Kloxin, professor of chemical and biomolecular engineering and materials science and engineering at the University of Delaware, has been named director of the Delaware Biotechnology Institute ...

Join leading experts at the analytica conference, showcasing advancements in analytical chemistry, bioanalytics, and ...

As Cytek Biosciences navigates its regulatory quiet period, the investment community is looking ahead to the imminent release of its complete fourth-quarter and ...

In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete ...

Quest expects the new blood test will support response monitoring in clinical trials.

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.